Search research articles
Contact Us
Filters
Showing results (11-20 of 474) with videos related to
Page
of 48
Sort By:
The Medico-Legal Journal
|
January 28, 2017
The changing prostate cancer pathway - new challenges, new pitfalls
Mark Emberton
The Lancet. Oncology
|
January 18, 2017
Is a negative prostate biopsy a risk factor for a prostate cancer related death?
Mark Emberton
BJU International
|
November 27, 2019
Translating cost-utility modelling into the real world - the case of focal high-intensity focussed ultrasound and active surveillance
Mark Emberton
The Journal of Urology
|
July 18, 2015
Why Focal Therapy is a Legitimate and Necessary Response to a Changing World
Mark Emberton
BJU International
|
March 2, 2006
Definition of at-risk patients: dynamic variables
Mark Emberton
BJU International
|
April 25, 2018
Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?
Mark Emberton
European Urology
|
December 20, 2025
Is Prostate-specific Antigen a Useful Triage Test Before Prostate Magnetic Resonance Imaging?
Mark Emberton
Nature Reviews. Urology
|
March 15, 2019
To see or not to see - what renders prostate cancer visible?
Mark Emberton
BJU International
|
July 20, 2019
Dropping the GAD - just a fad? The case for a simpler, quicker, safer and cheaper prostate magnetic resonance imaging
Mark Emberton
Current Opinion in Urology
|
December 31, 2005
To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?
Vibhash Mishra, Mark Emberton
Page
of 48
Search research articles
Search
Showing results (11-20 of 474) with videos related to
Sort By:
Page
of 48
The Medico-Legal Journal
|
January 28, 2017
The changing prostate cancer pathway - new challenges, new pitfalls
Mark Emberton
The Lancet. Oncology
|
January 18, 2017
Is a negative prostate biopsy a risk factor for a prostate cancer related death?
Mark Emberton
BJU International
|
November 27, 2019
Translating cost-utility modelling into the real world - the case of focal high-intensity focussed ultrasound and active surveillance
Mark Emberton
The Journal of Urology
|
July 18, 2015
Why Focal Therapy is a Legitimate and Necessary Response to a Changing World
Mark Emberton
BJU International
|
March 2, 2006
Definition of at-risk patients: dynamic variables
Mark Emberton
BJU International
|
April 25, 2018
Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?
Mark Emberton
European Urology
|
December 20, 2025
Is Prostate-specific Antigen a Useful Triage Test Before Prostate Magnetic Resonance Imaging?
Mark Emberton
Nature Reviews. Urology
|
March 15, 2019
To see or not to see - what renders prostate cancer visible?
Mark Emberton
BJU International
|
July 20, 2019
Dropping the GAD - just a fad? The case for a simpler, quicker, safer and cheaper prostate magnetic resonance imaging
Mark Emberton
Current Opinion in Urology
|
December 31, 2005
To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?
Vibhash Mishra, Mark Emberton
Page
of 48